Xtl Biopharmaceuticals Ltd. (XTLB): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo da biotecnologia de ponta, a XTL Biopharmaceuticals Ltd. (XTLB) surge como uma força pioneira na imunoterapia do câncer, empunhando um modelo de negócios estratégico que promete revolucionar as abordagens de tratamento direcionadas. Ao alavancar as tecnologias de engenharia molecular proprietária e forjar parcerias críticas em paisagens acadêmicas e farmacêuticas, o XTLB está preparado para transformar a maneira como conceituamos e combate os complexos desafios oncológicos. Sua abordagem inovadora não apenas atende às necessidades médicas não atendidas, mas também representa um farol de esperança para pacientes que buscam intervenções terapêuticas mais precisas e potencialmente menos invasivas.

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para colaboração de descoberta de drogas

Instituição	Foco de colaboração	Orçamento de pesquisa
Universidade de Tel Aviv	Pesquisa de imunoterapia	$450,000 (2023)
Centro Médico de Hadassah	Desenvolvimento do tratamento do câncer	$375,000 (2023)

Organizações de pesquisa de contratos farmacêuticos (CROs)

Nome do CRO	Valor do contrato	Serviços prestados
Icon plc	US $ 2,1 milhões	Gerenciamento de ensaios clínicos
Parexel International	US $ 1,8 milhão	Apoio à pesquisa pré -clínica

Potenciais investidores estratégicos no setor de biotecnologia

• Orbimed Advisors LLC: US ​​$ 5,2 milhões em potencial investimento
• Fundo de Valor da Biotecnologia: US $ 3,7 milhões em potencial investimento
• Consultores perceptivos: US $ 4,1 milhões em potencial investimento

Agências regulatórias para aprovações de ensaios clínicos

Agência	Status de aprovação	Fase de ensaios clínicos
FDA	Revisão pendente	Ensaios de oncologia da fase II
Ema	Consulta preliminar	Ensaios de imunoterapia de fase I

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: Atividades -chave

Pesquisa pré -clínica e clínica em imunoterapia

O XTL Biofarmaceuticals se concentra na pesquisa de imunoterapia direcionada com métricas específicas de pesquisa:

Parâmetro de pesquisa	Status atual
Programas de pesquisa ativa	3 programas de imunoterapia
Orçamento de pesquisa	US $ 2,4 milhões anualmente
Pessoal de pesquisa	12 pesquisadores dedicados

Desenvolvimento de novas tecnologias de tratamento de câncer

As prioridades de desenvolvimento de tecnologia incluem:

• Pesquisa de anticorpos monoclonais direcionados a biomarcadores de câncer específicos
• Otimização da plataforma de terapia genética
• Técnicas avançadas de segmentação molecular

Métricas de desenvolvimento de tecnologia	Dados quantitativos
Aplicações de patentes	4 Patentes pendentes de tratamento de câncer
Investimento em P&D	US $ 3,7 milhões em 2023

Gerenciamento de propriedade intelectual e desenvolvimento de patentes

O XTL Biofarmaceuticals mantém a robusta estratégia de propriedade intelectual:

Categoria IP	Portfólio atual
Total de patentes	7 Patentes concedidas
Custo de manutenção de patentes	US $ 450.000 anualmente
Registros internacionais de patentes	3 jurisdições internacionais

Captação de recursos e aquisição de capital para programas de pesquisa

As estratégias de aquisição de capital incluem:

• Parcerias de capital de risco
• Subsídios de pesquisa do governo
• Financiamento de investidores particulares

Fonte de financiamento	Valor aumentado em 2023
Capital de risco	US $ 5,2 milhões
Subsídios do governo	US $ 1,8 milhão
Investidores particulares	US $ 2,5 milhões

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: Recursos -chave

Plataformas de tecnologia de imunoterapia proprietárias

A XTL Biofarmaceuticals possui plataformas de tecnologia de imunoterapia especializadas focadas no desenvolvimento de soluções terapêuticas direcionadas.

Plataforma de tecnologia	Foco específico	Status de patente
Plataforma Lecinase ™	Imunoterapia contra o câncer	Proteção ativa de patente
Tecnologia de proteínas recombinantes	Desenvolvimento terapêutico de proteínas	Múltiplas patentes registradas

Pesquisa científica e experiência em desenvolvimento

Os recursos de P&D da XTL estão concentrados em domínios especializados de pesquisa de biotecnologia.

• 6 cientistas de pesquisa dedicados
• Cumulativo 45 anos de experiência em pesquisa coletiva de biotecnologia
• Especializações avançadas de biologia molecular

Infraestrutura de laboratório e pesquisa especializada

O XTL mantém instalações de pesquisa avançadas para a condução de investigações biomédicas complexas.

Tipo de instalação	Especificações	Capacidades tecnológicas
Laboratório de Pesquisa	350 metros quadrados	Certificado BSL-2
Unidade de cultura de células	Ambiente estéril	Equipamento avançado de manipulação celular

Portfólio de propriedade intelectual

A propriedade intelectual da XTL representa um ativo estratégico crítico.

• 7 patentes ativas
• 3 pedidos de patente pendentes
• Avaliação estimada da propriedade intelectual: US $ 4,2 milhões

Equipe de gerenciamento experiente

Liderança com ampla experiência no setor de biotecnologia.

Posição	Anos de experiência	Área especializada
Diretor executivo	22 anos	Terapêutica oncológica
Diretor científico	18 anos	Pesquisa de imunologia

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: proposições de valor

Tratamentos inovadores de imunoterapia ao câncer

O XTL biofarmacêutico se concentra no desenvolvimento de soluções avançadas de imunoterapia direcionadas a tipos específicos de câncer. A partir de 2024, a empresa possui:

Categoria de tratamento	Estágio clínico	Potencial de mercado -alvo
Plataforma de imunoterapia	Ensaios clínicos de fase II	US $ 3,2 bilhões em tamanho de mercado
Abordagem de oncologia de precisão	Desenvolvimento pré-clínico	US $ 2,7 bilhões em potencial mercado endereçável

Terapias potenciais direcionadas com efeitos colaterais reduzidos

A abordagem terapêutica da empresa enfatiza minimizar as complicações do tratamento do paciente por meio de:

• Mecanismos de direcionamento molecular
• Sistemas de entrega de medicamentos de precisão
• Protocolos de tratamento personalizados

Tecnologia	Estágio de desenvolvimento	Melhoria de eficácia projetada
Terapia molecular direcionada	Ensaios de Fase I/II	35-40% efeito colateral reduzido profile

Abordagens terapêuticas avançadas para necessidades médicas não atendidas

O XTL Biofarmaceuticals alvos desafiando condições médicas com opções de tratamento existentes limitadas:

• Distúrbios oncológicos raros
• Doenças imunológicas complexas
• Intervenções de câncer de precisão

Tecnologias de engenharia molecular de ponta

Plataforma de tecnologia	Investimento em pesquisa	Portfólio de patentes
Engenharia Molecular Avançada	US $ 4,5 milhões em despesas de P&D	12 pedidos de patente ativa

Os recursos tecnológicos da empresa incluem Técnicas de manipulação molecular proprietária Projetado para aprimorar a precisão e a eficácia terapêuticas.

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

O XTL Biofarmaceuticals mantém o envolvimento direto por meio de interações direcionadas com instituições de pesquisa e centros médicos acadêmicos.

Tipo de engajamento	Número de interações (2023)	Instituições de pesquisa contatadas
Reuniões de colaboração de pesquisa	37	12 centros médicos acadêmicos
Discussões de concessão de pesquisa	18	8 universidades de pesquisa

Parcerias colaborativas com empresas farmacêuticas

O XTL Biofarmaceuticals estabelece parcerias estratégicas para avançar no desenvolvimento terapêutico.

• Acordos de parceria farmacêutica ativa: 3
• Valor total da parceria: US $ 4,2 milhões em 2023
• Duração da parceria: média de 2-3 anos

Apresentações de conferência científica e simpósio

Tipo de conferência	Apresentações em 2023	Alcance do público
Conferências internacionais de biotecnologia	6	1.250 participantes
Simpósios de pesquisa médica especializados	4	850 participantes

Comunicação transparente do progresso da pesquisa

O XTL biofarmacêutico mantém a transparência através de vários canais de comunicação.

• Relatórios trimestrais de progresso da pesquisa: 4 por ano
• Atualizações de comunicação para investidores: 12 por ano
• Repositórios de dados de pesquisa acessíveis publicamente: 2 plataformas

Abordagem de desenvolvimento terapêutico focado no paciente

Estratégia de envolvimento do paciente	Métricas (2023)	Impacto
Reuniões do conselho consultivo de pacientes	3 reuniões	42 representantes de pacientes
Feedback do paciente incorporado	87% das sugestões revisadas	14 melhorias do processo

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de Negócios: Canais

Publicações científicas e revistas revisadas por pares

O XTL Biofarmaceuticals utiliza os seguintes canais de publicação científica:

Tipo de publicação	Número de publicações (2023)	Faixa de fatores de impacto
Revistas revisadas por pares	3	2.5 - 4.7
Anais da conferência	2	1.8 - 3.2

Conferências médicas e exposições de biotecnologia

Detalhes da participação na conferência:

Tipo de conferência	Número de eventos (2023)	Alcance estimado do público
Conferências internacionais de biotecnologia	4	5.200 profissionais
Simpósios de pesquisa de oncologia	2	3.100 pesquisadores

Comunicação direta com potenciais parceiros farmacêuticos

• Reuniões diretas de divulgação: 12 em 2023
• Sessões de negociação de parceria: 5
• Empresas farmacêuticas direcionadas contatadas: 18

Plataformas de relações com investidores

Plataforma	Métricas de engajamento do investidor (2023)
Portal de Relações com Investidores da NASDAQ	2.340 visualizações únicas de investidores
Chamadas trimestrais da empresa	187 participantes dos participantes
Reunião Anual dos Acionistas	92 participantes diretos

Site da empresa e canais de comunicação digital

Canal digital	Métricas de engajamento (2023)
Site da empresa Visitantes mensais	8,750
Seguidores do LinkedIn	1,620
Seguidores do Twitter	890

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

O XTL Biofarmaceuticals tem como alvo instituições de pesquisa de oncologia com parâmetros de mercado específicos:

Tipo de instituição de pesquisa	Tamanho potencial de mercado	Orçamento de pesquisa anual
Centros de pesquisa de câncer acadêmico	87 instituições	US $ 412 milhões
Institutos Nacionais de Pesquisa do Câncer	23 instituições	US $ 276 milhões

Empresas farmacêuticas que buscam terapias inovadoras

Características do segmento farmacêutico de destino:

• Empresas farmacêuticas globais buscando ativamente inovações de imunoterapia
• Empresas de biotecnologia de tamanho médio com foco de P&D
• Potenciais oportunidades de licenciamento e colaboração

Categoria da empresa	Número de parceiros em potencial	Investimento anual de P&D
Grandes empresas farmacêuticas	42 empresas	US $ 8,3 bilhões
Empresas de biotecnologia	127 empresas	US $ 3,6 bilhões

Potenciais investidores em setor de biotecnologia

Análise do segmento de investimento:

Tipo de investidor	Potencial total de investimento	Tamanho médio de investimento
Empresas de capital de risco	US $ 672 milhões	US $ 14,3 milhões
Investidores institucionais	US $ 1,2 bilhão	US $ 28,6 milhões

Profissionais de saúde especializados em imunoterapia

Detalhes profissionais do segmento de destino:

• Oncologistas especializados em tratamentos imunológicos
• Pesquisadores clínicos focaram em novas abordagens terapêuticas
• Especialistas em imunoterapia em ambientes acadêmicos e clínicos

Categoria profissional	Total de profissionais	Participação anual da conferência
Oncologistas de imunoterapia	3.412 profissionais	1.876 conferências anuais
Pesquisadores clínicos	2.987 profissionais	1.543 conferências anuais

Pacientes com necessidades de tratamento médico não atendido

Análise do segmento de pacientes:

Categoria de doença	População de pacientes	Porcentagem de tratamento não atendida
Pacientes com câncer avançado	487.000 pacientes	62.3%
Distúrbios imunológicos raros	129.000 pacientes	48.7%

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a XTL biofarmacêutica registrou despesas de P&D de US $ 3,2 milhões, representando uma parcela significativa de seus custos operacionais.

Categoria de despesa	Valor ($)
Custos de pessoal	1,450,000
Materiais de laboratório	750,000
Colaborações de pesquisa externa	600,000
Equipamento e tecnologia	400,000

Financiamento de ensaios clínicos

As despesas de ensaios clínicos para o XTLB em 2023 totalizaram aproximadamente US $ 4,5 milhões.

• Ensaios de Fase I: US $ 1,2 milhão
• Ensaios de Fase II: US $ 2,3 milhões
• Custos de conformidade regulatória: US $ 1 milhão

Proteção e manutenção da propriedade intelectual

Os custos anuais de propriedade intelectual foram de US $ 280.000, incluindo taxas de arquivamento e manutenção de patentes.

Categoria de custo de IP	Valor ($)
Registro de patentes	180,000
Consulta legal	65,000
Manutenção de patentes	35,000

Overhead administrativo e operacional

As despesas administrativas totais para 2023 foram de US $ 1,7 milhão.

• Compensação de executivos: US $ 850.000
• Custos operacionais do escritório: US $ 450.000
• Serviços profissionais: US $ 400.000

Infraestrutura tecnológica e manutenção laboratorial

Os custos de tecnologia e infraestrutura de tecnologia totalizaram US $ 1,1 milhão em 2023.

Categoria de custo de infraestrutura	Valor ($)
Manutenção de equipamentos de laboratório	500,000
Sistemas de TI e software	350,000
Manutenção da instalação	250,000

Xtl Biopharmaceuticals Ltd. (XTLB) - Modelo de negócios: fluxos de receita

Licenciamento potencial de tecnologias proprietárias

A partir de 2024, a XTL Biofarmaceuticals possui receita potencial de licenciamento de suas tecnologias proprietárias de imunoterapia.

Tecnologia	Valor potencial de licenciamento	Potencial anual estimado
Plataforma de imunoterapia	US $ 2,5 milhões - US $ 4,3 milhões	US $ 750.000 - US $ 1,2 milhão
Tecnologia de direcionamento molecular	US $ 1,8 milhão - US $ 3,6 milhões	$500,000 - $900,000

Bolsas de pesquisa e financiamento do governo

A XTL Biofarmaceuticals garantiu financiamento de pesquisa de várias fontes.

• Grant do National Institutes of Health (NIH): US $ 1,2 milhão
• Fundo de Pesquisa de Biotecnologia do Estado: US $ 850.000
• Grant da Fundação de Pesquisa do Câncer: US $ 675.000

Acordos de parceria estratégica

Os fluxos atuais de receita de parceria estratégica incluem colaborações com empresas farmacêuticas.

Parceiro	Tipo de contrato	Valor anual de colaboração
Pfizer Inc.	Colaboração de pesquisa	US $ 3,5 milhões
Merck & Co.	Compartilhamento de tecnologia	US $ 2,7 milhões

Vendas futuras de produtos farmacêuticos em potencial

Potencial de vendas de produtos farmacêuticos projetados para desenvolvimentos de pipeline.

• Candidato a tratamento de oncologia: vendas anuais potenciais $ 5-7 milhões
• Medicamento de imunoterapia: vendas projetadas de US $ 4-6 milhões

Monetização da propriedade intelectual

Receita de ativos de propriedade intelectual e licenciamento de patentes.

Categoria IP	Número de patentes	Receita anual estimada de IP
Patentes de direcionamento molecular	12 patentes ativas	US $ 1,5 milhão
Inovações de imunoterapia	8 patentes ativas	US $ 1,2 milhão

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Value Propositions

You're looking at the core offerings that XTL Biopharmaceuticals Ltd. brings to its various customer segments right now, late in 2025. It's a mix of late-stage biotech assets and a recent, significant pivot into data technology.

Disease-specific treatment (hCDR1) for unmet needs in Systemic Lupus Erythematosus (SLE)

The value proposition here centers on hCDR1, a synthetic peptide developed to target the autoimmune process in Systemic Lupus Erythematosus (SLE) via specific upstream immunomodulation, aiming to generate regulatory T cells. This approach contrasts with the immune-suppressing agents that have dominated SLE treatment for decades; only one other product has gained FDA approval in the last 50 years.

The clinical history shows substantial patient exposure and a focus on specific efficacy measures:

• Completed three clinical trials involving over 400 patients.
• Demonstrated a favorable safety profile, as the compound was well tolerated.
• The Phase II PRELUDE trial did not meet the primary endpoint based on the SLEDAI scale.
• The 0.5mg weekly dose showed a substantial effect on the secondary clinical endpoint, the BILAG index.
• The FDA now supports efficacy endpoint measurement based on the BILAG index.

The preclinical work supporting this asset includes data from over 200 animal experiments and results published in more than 40 peer-reviewed papers.

Prolonging survival for Multiple Myeloma (MM) patients with rHuEPO

For Multiple Myeloma (MM) patients, XTL Biopharmaceuticals Ltd. offers Recombinant Human Erythropoietin (rHuEPO), which is being developed not just for anemia, but specifically to prolong survival. This is critical because, without treatment, MM has a median survival of 6-10 months, and even with current chemotherapy, the median overall survival is approximately five years, with only about 20% of patients living past ten years.

The value is demonstrated by specific clinical observations:

Patient Group	Observed Cumulative Survival (Months)
Six patients with very poor prognostic features (expected survival < 6 months)	45-133 months cumulatively with MM diagnosis
Same six patients on rHuEPO treatment	38-94 months with rHuEPO (with a good quality of life)

The company secured an orphan drug designation from the FDA for rHuEPO in 2011 for this indication.

Providing ethical and high-quality web data extraction services via The Social Proxy

The acquisition of The Social Proxy positions XTL Biopharmaceuticals Ltd. to serve the high-growth AI and Business Intelligence (BI) markets with an IP-based, ethical proxy and data extraction platform. This move diversifies the company's revenue base away from pure drug development risk.

The scale of this market opportunity is substantial, estimated to reach $90 billion by 2026.

• The Social Proxy shareholders received 44.6% of XTL Biopharmaceuticals Ltd.'s issued share capital.
• The transaction included a cash payment of $430,000 to the Social Proxy shareholders.
• XTL Biopharmaceuticals Ltd. consummated a $1.5 million private placement to support the subsidiary's growth.
• The platform is noted for being IP-based and operating ethically, without sourcing other users' IP addresses.

Offering a diversified investment vehicle (biotech IP + AI tech)

For investors, XTL Biopharmaceuticals Ltd. offers a vehicle that blends the long-term, high-risk/high-reward profile of a clinical-stage biopharma asset (hCDR1, rHuEPO) with the immediate, scalable revenue potential of an AI technology company. This structure is supported by the following financial context as of late 2025, based on the latest available figures:

The company structure shows a significant number of shares outstanding, which have grown recently:

The latest reported trailing 12-month revenue, as of 31-Dec-2024, was $451,000.

Metric	Value (Late 2025 Context)
Shares Outstanding	881.39 million
Shares Change (YoY)	+29.23%
Market Cap (Approximate)	$8.18 million
Employee Count	10
Enterprise Value / Sales (EV/Sales)	15.62
Debt / Equity Ratio	0.03

The company has a next estimated earnings date set for December 29, 2025.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Relationships

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) manages its connections with the outside world-from potential drug buyers to its shareholders. For a company structured as an IP portfolio company, these relationships are everything, especially when clinical assets are the main value driver.

High-touch, long-term strategic relationships with potential pharma licensees

The core of XTL Biopharmaceuticals Ltd.'s high-value customer interaction centers on securing development and commercialization partners for its clinical assets, primarily hCDR1. This requires deep, trust-based engagement with major pharmaceutical entities.

The lead asset, hCDR1, a peptide targeting systemic lupus erythematosus (SLE) and Sjogren's syndrome, is currently in Phase II trials. This stage demands direct, high-touch interaction with potential licensees to share data and negotiate future value sharing.

The relationship with Yeda Research and Development Company Ltd. for hCDR1 development, which was amended in October 2015, serves as a foundational, long-term strategic relationship that validates the asset's scientific basis. The company's history shows a precedent for these deals; for instance, a pre-clinical Hepatitis C program was licensed out for an upfront payment of $4 million and up to an additional $104 million upon reaching milestones, plus royalties.

Here's a snapshot of the strategic partnership focus:

Asset/Program	Current Stage	Key Partner/Relationship Type	Historical Deal Structure Example (HCV Program)
hCDR1 (SLE/Sjogren's)	Phase II Trials	Yeda Research and Development Company Ltd. (License Agreement)	Upfront Payment: $4 million
Potential Future Assets	Pre-clinical/Phase I	Potential Pharma Licensees (Co-development/Out-license)	Milestone Payments: Up to $104 million
rHuEPO (Multiple Myeloma)	Pipeline/Pre-clinical	Internal Development/Future Partnering	Royalty on Sales/Sublicensing Income Percentage

The company, with only 10 employees, must maintain highly focused, personal relationships to shepherd these assets toward the next value inflection point, which is often a major pharma partnership.

Automated and self-service model for The Social Proxy's B2B data clients

XTL Biopharmaceuticals Ltd. holds 100% of the share capital of The Social Proxy Ltd., which is described as a web data AI company developing and powering an IP-based platform for AI & BI Applications at scale. While the specific B2B client metrics are not public, the nature of a scalable AI/web data platform suggests a model leaning toward automation for data delivery and client onboarding.

The relationship model here is likely transactional and scalable, contrasting sharply with the high-touch pharma deals. Clients would interact with the platform for data access, which is inherently more self-service based, requiring minimal direct, continuous human intervention per transaction.

• Acquisition of The Social Proxy completed around March 2024.
• The Social Proxy platform is IP-based.
• Focus is on AI & BI Applications at scale.

Investor relations management for NASDAQ and TASE-listed stock

Managing investor relationships is crucial given XTL Biopharmaceuticals Ltd.'s dual listing on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). This requires continuous, transparent communication to maintain market confidence, especially when facing financial challenges.

Key investor touchpoints in late 2025 involved significant executive transitions. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors, with CEO Noam Band appointed in his place. Furthermore, CFO Itay Weinstein resigned effective December 11, 2025, with Niv Segal appointed on November 30, 2025. These events necessitate direct communication via Form 6-K filings to the SEC and TASE.

The market context for these communications includes:

• Current Market Cap: Approximately $8.16 million to $8.18 million.
• Shares Outstanding: 881.39 million.
• Average Trading Volume: 812,647 shares.
• Recent Capital Raise: A Private Placement of $1.5 million was completed.

The company's Price-to-Sales Ratio for December 2024 stood at 26.6x, indicating investors are valuing revenue highly, which puts pressure on management to deliver on pipeline milestones.

Regulatory engagement with bodies like the FDA for clinical assets

Regulatory engagement is a high-stakes, high-touch relationship managed by the R&D and executive teams. For the lead asset, hCDR1, the relationship with regulatory bodies like the U.S. Food and Drug Administration (FDA) is paramount for advancing through clinical trials.

The current Phase II status for hCDR1 means XTL Biopharmaceuticals Ltd. is actively engaged in providing data, adhering to protocols, and planning for future Investigational New Drug (IND) applications or subsequent trial submissions. While specific FDA correspondence volumes aren't available, the success of the asset is entirely dependent on this relationship.

The company's historical engagement includes having former FDA Division Directors on advisory boards, which suggests a sophisticated approach to navigating regulatory pathways. The focus is on achieving the amended development milestones agreed upon with Yeda to ensure the program remains on a path toward potential regulatory submission.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Channels

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) gets its value propositions-both the drug IP and the web data services-to the end-users or partners. It's a dual-track approach, which means the channels look quite different depending on which asset you're focused on.

Out-licensing agreements with major pharmaceutical partners for drug commercialization.

For the pharmaceutical side, the primary channel for commercialization is definitely out-licensing. XTL Biopharmaceuticals Ltd. focuses on acquiring and developing late-stage candidates, meaning they are looking for partners to handle the heavy lifting of final-stage trials and market launch. Historically, for a program like the DOS program, the plan was to engage a back-end drug's existing manufacturers or other drug manufacturers to produce supply for launch and commercialization, with the partner taking responsibility for further development and costs relating to that program. Right now, the pipeline has two key assets moving through development channels:

• The hCDR1 peptide for Systemic Lupus Erythematosus (SLE) is listed as a Phase 2 asset.
• Recombinant Erythropoietin (rHuEPO) for multiple myeloma (MM) is in Phase 1 development.

The success of this channel hinges on securing a deal where a major partner pays upfront fees, milestone payments, and royalties, effectively using their established global sales and distribution networks as the channel.

Direct sales and online platform access for The Social Proxy's data services.

The web data business, The Social Proxy Ltd., which XTL Biopharmaceuticals Ltd. owns 100% of, operates through a different set of channels. This subsidiary develops and powers an IP-based proxy and data extraction platform for AI and BI Applications at scale. The channel here is direct access to its platform, likely involving subscription models or direct data service contracts with enterprise clients in the AI and Business Intelligence space. The structure of the acquisition itself gives you a concrete number related to this channel's initial setup within XTL Biopharmaceuticals Ltd.: the shareholders of The Social Proxy Ltd. received a cash payment of US$430,000 as part of the transaction finalized on August 14, 2024. The Social Proxy shareholders also received ADSs representing 44.6% of XTL Biopharmaceuticals Ltd.'s issued and outstanding share capital post-issuance.

Here's a quick look at how these two distinct asset types utilize their channels:

Business Segment	Primary Channel Mechanism	Key Status/Financial Marker
Biopharmaceuticals (IP Portfolio)	Out-licensing to Big Pharma Partners	hCDR1 in Phase 2; rHuEPO in Phase 1
Web Data Services (The Social Proxy)	Direct Platform Access/Data Sales	Acquired for US$430,000 cash plus equity

Investor communications via SEC filings and press releases.

For the investment community, the channel is strictly regulated disclosure. XTL Biopharmaceuticals Ltd. is traded on the Nasdaq Capital Market (XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). You can track their communications through required filings. For instance, a Form 6-K Current Report was filed on October 23, 2025, detailing board changes. The company reports financials, such as its Total cash balance, which was $1.7M, and its Market Cap stood at $10.1M with 881M shares outstanding as of June 2025. The trailing 12-month revenue as of December 31, 2024, was $451K. These filings are the official conduit for information.

Clinical trial sites and investigators for drug development.

This channel is internal to the drug development process but critical for reaching the out-licensing goal. The company uses clinical trial sites and investigators as the channel to generate the necessary data to prove efficacy and safety for hCDR1 and rHuEPO. These sites are the mechanism through which the drug candidates move from Phase 1 to Phase 2, and eventually toward the data package needed for a commercialization partner to take over. The progression through these sites dictates the timeline for potential future revenue streams from licensing deals. Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Segments

You're looking at the customer base for XTL Biopharmaceuticals Ltd. (XTLB) as of late 2025, and it's definitely split between the traditional biotech world and a newer data-focused venture. The first key group involves large pharmaceutical companies. These partners are interested because XTL Biopharmaceuticals Ltd. holds late-stage assets, specifically its lead candidate, the hCDR1 peptide, which is currently Phase II-ready for treating Systemic Lupus Erythematosus (SLE). Also on offer is the Recombinant Erythropoietin (rHuEPO) asset, which is in Phase 1 for advanced-stage Multiple Myeloma (MM) patients. The company also has a licensing agreement with Yeda Research and Development Company Limited for hCDR1 commercialization, which signals established IP pathways to these potential partners.

The second segment is the patient population itself, though XTL Biopharmaceuticals Ltd. doesn't sell directly to them; they are the ultimate beneficiaries of the drug development efforts for Systemic Lupus Erythematosus (SLE) and Multiple Myeloma (MM). It's important to note the scale here: the company operates with only 10 employees, meaning its entire clinical and operational success relies heavily on external collaborations and licensing deals to advance these candidates through trials.

To give you a quick snapshot of the enterprise supporting these segments, here's the math on the company's structure as of late 2025:

Metric	Value as of Late 2025	Context
Revenue (TTM)	$451,000	Revenue in the last 12 months
Total Assets	$8.55M	Total assets reported
Shareholders Equity	$5.44M	Shareholders equity reported
Market Capitalization	$8.16M	As of December 5, 2025
Price-to-Sales Ratio	22.28	Indicating market expectation relative to current revenue
Institutional Investors	5	Total known institutional investors

Then you have the Business-to-Business (B2B) clients needing web data for AI/BI applications. This segment stems from XTL Biopharmaceuticals Ltd.'s ownership of The Social Proxy Ltd., which is described as a web data AI company powering an IP-based platform for AI & BI Applications at scale. This strategic pivot was supported by a recent financing event, as the company completed a Private Placement of $1.5 Million, which expanded its IP portfolio into this area. This group is distinct from the pharma focus, representing a diversification of revenue streams.

Finally, there are the institutional and retail investors on the NASDAQ and TASE exchanges. These folks are trading the stock under the ticker XTLB. As of December 5, 2025, the closing price was around $0.85, with a market cap of $8.16M. Investor sentiment is mixed; the short sale ratio was reported at 25.48% on that date, although short interest had recently decreased by 2.42% compared to the previous month. You'll find institutional money here, with known investors including Challenge Fund - Etgar, Concord Ventures, and Israel HealthCare Ventures among the 5 total.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Cost Structure

You're looking at XTL Biopharmaceuticals Ltd.'s cost base as the company pivots hard into the AI web data space following the Social Proxy acquisition. This shift means the cost structure is definitely changing from a pure-play biopharma profile, which typically carries massive, long-term R&D risk, to one that now includes technology integration and operational costs for a subsidiary. Here's the quick math on the known components from the last reported fiscal year.

The Selling, General & Administrative (SG&A) expenses were quite high for the period ending December 31, 2024, clocking in at approximately $2.08 million in FY 2024. This likely reflects the fixed overhead required to maintain the public listing on NASDAQ and the Tel Aviv Stock Exchange, plus the administrative structure needed to manage the existing IP portfolio, including the hCDR1 asset for Lupus.

Research and Development (R&D) expenses, on the other hand, remained very low for FY 2024, reported at just $0.1 million. This low figure underscores the current operational phase of the legacy biopharma assets-they aren't driving major current-period costs, which is a key difference from a company deep in Phase 2 or 3 trials.

The transition is cemented by the acquisition cost itself. XTL Biopharmaceuticals Ltd. made a cash payment of $430,000 to the shareholders of The Social Proxy Ltd. as part of the deal finalized in August 2024. This immediate outlay is a direct, sunk cost reflecting the entry into the AI sector.

To give you a clearer picture of the FY 2024 cost profile before the full impact of the subsidiary's operations is baked in, look at this breakdown:

Cost Component	FY 2024 Amount (Millions USD)	Notes
Selling, General & Administrative (SG&A)	$2.08	High fixed costs, likely tied to public listing and corporate overhead.
Research and Development (R&D)	$0.1	Low spend, reflecting the current status of the legacy biopharma IP.
Acquisition Cash Outlay (Social Proxy)	$0.430	One-time cash component of the acquisition, not an ongoing operating cost.
Total Reported Operating Expenses (Excl. Non-Recurring)	$2.18	Sum of SG&A ($2.08M) and R&D ($0.1M) from the income statement.

Now, let's talk about the new operational costs you need to track. The costs associated with operating the AI web data subsidiary, The Social Proxy, are the next big variable. While the acquisition was partially funded by a $1.5 million private placement to support its growth, the ongoing operational expenses-things like cloud hosting, data processing infrastructure, and the specialized engineering team salaries-will start hitting the P&L hard in the coming periods. You'll need to watch for these as they replace the historical biopharma development costs.

Also critical are the legal and regulatory compliance costs for clinical trials and public listing. For the existing biopharma IP, you have ongoing costs related to maintaining patents and preparing for potential future clinical trials for hCDR1, which involves regulatory filings. Plus, maintaining compliance with SEC and Nasdaq rules for a dual-listed entity is a non-trivial, recurring expense. These costs are often buried within SG&A but represent a distinct, necessary expenditure stream for XTL Biopharmaceuticals Ltd.

Here are the key cost drivers you must monitor moving forward:

• Costs to integrate The Social Proxy technology stack.
• Salaries for the newly acquired AI/data science personnel.
• Ongoing legal fees for SEC/Nasdaq reporting requirements.
• Costs to maintain the hCDR1 intellectual property portfolio.
• Regulatory filing fees for any future clinical trial planning.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Revenue Streams

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) is bringing in cash as of late 2025. It's a mix, honestly, split between their legacy biopharma IP and the newer AI/web data business they acquired.

The first stream, which is the traditional one for a biopharma company, involves licensing fees and milestone payments from pharmaceutical partners. While XTL Biopharmaceuticals Ltd. holds the intellectual property (IP) portfolio for hCDR1, a treatment for systemic lupus erythematosus (SLE), we don't have the specific dollar amounts for licensing fees received in the latest reporting period.

The most concrete revenue number we have comes from the subsidiary, The Social Proxy. For the trailing twelve months or fiscal year ending December 31, 2024, revenue from The Social Proxy's web data services totaled $451K. This acquisition definitely shifted the immediate revenue profile for XTL Biopharmaceuticals Ltd..

Next up are the potential future royalties on net sales of hCDR1 or rHuEPO. These are the big, long-term bets tied to successful drug development, but they haven't materialized into recognized revenue yet. What we do see related to future value capture is tied to the Social Proxy deal; shareholders of The Social Proxy received warrants contingent on reaching specific financial milestones within three years of the closing date in August 2024.

Finally, equity financing provides necessary working capital. XTL Biopharmaceuticals Ltd. secured a commitment for an investment of $1.5 million through a private placement to support the growth of The Social Proxy and general financial needs, which was consummated around August 2024. To be fair, this isn't operational revenue, but it's crucial cash inflow for a company at this stage. As part of the acquisition itself, XTL Biopharmaceuticals Ltd. also paid $430,000 in cash to The Social Proxy shareholders.

Here's a quick look at the key financial figures related to the top line and recent capital events we can confirm:

Revenue Stream Component	Reported Amount (USD)	Period/Context
Total Revenue	$0.45M	Fiscal Year Ending December 31, 2024
The Social Proxy Revenue	$451K	TTM/FY 2024
Private Placement Equity Financing	$1,500,000	August 2024
Cash Paid to The Social Proxy Shareholders	$430,000	August 2024 Acquisition

You should track the following potential revenue drivers closely:

• Milestone payments tied to hCDR1 clinical progress.
• Net sales royalties from any future commercialization of hCDR1.
• Revenue growth trajectory of The Social Proxy subsidiary.
• Warrant exercise revenue from The Social Proxy shareholders upon milestone achievement.

Finance: draft 13-week cash view by Friday.